DEA schedule
Is Xultophy 100/3.6 a controlled substance?
Xultophy 100/3.6 contains insulin degludec and liraglutide. Federal schedule from the FDA NDC directory, checked against the DEA controlled substances list.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
No. Xultophy 100/3.6 (insulin degludec and liraglutide) is not a federally controlled substance. None of its FDA NDC listings carries a DEA schedule, and insulin degludec and liraglutide is not on the DEA controlled substances list.
Run it in Rivvi
Which 2027 plans near you dropped or restricted Xultophy 100/3.6?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Schedule check
| Source | What it lists |
|---|---|
| FDA NDC directory | 1 prescription listings from 1 labelers, none with a DEA schedule |
| DEA controlled substances list | insulin degludec and liraglutide is not on the list |
Xultophy 100/3.6 NDC listings
| NDC | Product | Form | Strength | Labeler | DEA schedule |
|---|---|---|---|---|---|
| 0169-2911 | Xultophy 100/3.6 | injection, solution | 100 [iU]/mL; 3.6 mg/mL | Novo Nordisk | None |
Questions
Is Xultophy 100/3.6 a controlled substance?
No. Xultophy 100/3.6 (insulin degludec and liraglutide) is not a federally controlled substance. None of its FDA NDC listings carries a DEA schedule, and insulin degludec and liraglutide is not on the DEA controlled substances list.
Is Xultophy 100/3.6 a narcotic?
No. Xultophy 100/3.6 (insulin degludec and liraglutide) is not on the DEA controlled substances list, so the DEA does not classify it as a narcotic. Its FDA established pharmacologic class is GLP-1 Receptor Agonist and Insulin Analog.
Does this page cover state schedules?
No. This page reports the federal schedule only. Some states schedule drugs on their own; check your state board of pharmacy.